TRDA VS BCYC Stock Comparison

Performance

TRDA
10/100

TRDA returned -10.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BCYC
10/100

BCYC returned -45.68% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

TRDA
71/100

TRDA receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

BCYC
43/100

BCYC receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

TRDA
10/100

TRDA has missed earnings 4 times in the last 20 quarters.

BCYC
10/100

BCYC has missed earnings 12 times in the last 20 quarters.

Profit

TRDA
10/100

Out of the last 13 quarters, TRDA has had 1 profitable quarters and has increased their profits year over year on 1 of them.

BCYC
10/100

Out of the last 20 quarters, BCYC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

TRDA
51/100

TRDA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

BCYC
46/100

BCYC has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Sentiment

TRDA

"Sentiment" not found for TRDA

BCYC
67/100

BCYC had a bullish sentiment score of 66.67% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Entrada Therapeutics, Inc. Common Stock Summary

Nasdaq / TRDA

Healthcare

Biotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Bicycle Therapeutics plc American Depositary Shares Summary

Nasdaq / BCYC

Healthcare

Biotechnology

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Power up your portfolio